FINWIRES · TerminalLIVE
FINWIRES

CIBC發布Shopify第一季業績預覽;表示預計本季業績強勁,並展望2026年前景。

-- 加拿大帝國商業銀行資本市場(CIBC Capital Markets)重申了對Shopify (SHOP.TO, SHOP)股票的「跑贏大盤」評級和185美元的目標價,並發布了該公司第一季度業績展望。 CIBC表示,Shopify將於5月5日公佈第一季業績,隨後召開電話會議。 CIBC預計,在支付業務、新增商家以及歐洲市場強勁成長的支撐下,SHOP將達到或超過市場預期第一季業績,並提供正面的第二季業績指引。 CIBC指出:“我們的替代數據強化了這一觀點,並表明第一季度的增長勢頭延續到了第二季度初:此外,我們追踪的商戶在4月份的網站流量同比增長加速至約25%(第一季度為20%,上一季度約為17%;數據截至4月11日)。” CIBC補充道,這支撐了GMV的成長,並使SHOP有望超越營收成長和自由現金流利潤率的預期。 「我們的展望是基於商家解決方案業務的快速成長(抵銷訂閱解決方案業務的放緩),這得益於CIBC針對Plus商戶的另類資料趨勢、歐洲、中東和非洲地區的強勁成長勢頭、企業和零售POS系統的普及以及人工智慧的集成,」CIBC補充道。 「主要抵銷因素包括產品組合帶來的毛利率壓力(支付業務)以及研發和行銷再投資帶來的營運支出增加;我們還假設第一季度稅率較高,並將在2026年晚些時候恢復正常。” CIBC指出,自2025年3月以來,SHOP的營收平均超出市場預期約3%,自由現金流平均超出市場預期約4%。 CIBC表示,關鍵風險仍然是能否實現10%左右的自由現金流利潤率預期,而FactSet目前的預測表明,該利潤率將低於2025年第一季的預期。 「我們的目標價為185美元,基於我們2027年銷售額預測的12倍,加上現金和其在Flexport的股權,」CIBC補充道。 “SHOP 的 X 法則(2 倍增長率 + 自由現金流利潤率)在 BVP 納斯達克新興雲指數的同類成分股中繼續名列前茅,從而支撐了其溢價倍數。”

Price: $176.40, Change: $+1.21, Percent Change: +0.69%

Related Articles

Asia

Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%

Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.

$ASX:ONE
Asia

Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low

Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.

$ASX:PAR
Asia

Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%

Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.

$SHA:600703